Researchers at UC San Diego have developed DeepHRD, an AI tool that identifies homologous recombination deficiency in tumors from standard biopsy slides, achieving three times the accuracy of traditional genomic tests while avoiding their high failure rates. Retrospective studies show that precision medicine guided by such tools improves survival in breast, lung, and pancreatic cancers compared with standard therapies.
Artificial intelligence is increasingly transforming cancer detection and treatment. Platforms like Prov-GigaPath, Owkin systems, CHIEF, and HistoPathXplorer enhance diagnostic accuracy, while AlphaFold 3 predicts biomarkers, and Paige Prostate Detect improves prostate biopsy interpretation. Tools such as MSI-SEER identify mutations often missed by conventional testing, expanding patient access to immunotherapy. AI now integrates clinical, imaging, and genomic data to provide evidence-based treatment recommendations and more accurate outcome predictions.
Immunotherapy advances complement these tools. Perioperative pembrolizumab reduced recurrence in head and neck cancer by 34% in the KEYNOTE-689 trial. New approvals include retifanlimab for anal cancer, bispecific antibodies like Lynozyfic for multiple myeloma, and ADCs such as Emrelis, Datroway, Enhertu, and Adcetris. Tecelra became the first FDA-approved engineered TCR therapy for synovial sarcoma, while CAR T-cell trials continue expanding.